ArticleClinics and practice2022
Plasma Rich in Growth Factors in Macular Hole Surgery.
Article in Clinics and practice, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT06323902 (Clinical Evidence of Autologous Platelet-Rich Plasma as a Treatment for Macular Holes), which is not on this map. Cited by 6 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Clinical Evidence of Autologous Platelet-Rich Plasma as a Treatment for Macular Holes
Who cites it
6 citing papers in PubMed.
- Anatomical and Functional Outcomes of Platelet-Rich Plasma-Assisted Surgery for Full-Thickness Macular Holes: A Retrospective Real-World Cohort Study.Journal of clinical medicine · 2026Article
- Platelet concentrates in macular hole surgery. A journey through the labyrinth of terminology, preparation, and application: a comprehensive review.Graefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie · 2024Review
- Safety of intraoperative autologous plasma incubation of corneal grafts for reducing endothelial cell loss: a pilot study.Frontiers in medicine · 2024Article
- Plasma Rich in Growth Factors as an Adjuvant Agent in Non-Penetrating Deep Sclerectomy.Journal of clinical medicine · 2023Article
- Autologous blood as an adjuvant to inverted internal limiting membrane flaps in closure of a large traumatic macular hole.Oman journal of ophthalmologyArticle
- Anatomical and functional results of plasma rich in growth factors as a treatment for poor-prognosis macular holes.Romanian journal of ophthalmologyArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The aim of this study was to evaluate the use of PRGF (plasma rich in growth factors) as an adjuvant to PPV (pars plana vitrectomy) in recurrent, persistent, or poor prognosis MH (macular hole). Patients with MH were treated with PPV plus adjuvant therapy (PRGF membrane (mPRGF) and injectable liquid PRGF (iPRGF)). The anatomical closure of MH and postoperative BCVA (best-corrected visual acuity) were evaluated. Eight eyes (eight patients) were evaluated: myopic MH (MMH,
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.